Record Growth, Reaffirmed Guidance — The Dahej Wager Begins
J.G. Chemicals delivered 64% revenue growth and 86% PAT growth, hitting every near-term target. Yet management maintained, rather than raised, its three-year guidance. The gap between execution and outlook is the story — and the market, down 17% from ATH, is skeptical.
₹361.0 Cr
+63.9% YoY, +14.4% QoQ
₹28.0 Cr
+85.9% YoY, +7.0% QoQ
10.71%
vs 11.07% Q1; tracking 11-12% Phase 1 target
>80%
October highest production ever
J.G. Chemicals delivered its strongest quarter on record — ₹361 Cr revenue, ₹28 Cr PAT — and is executing against every near-term commitment. Yet the real story is not the headline numbers. It's the gap between what management delivered and what it chose not to promise: despite 64% YoY revenue growth and 86% PAT growth, management reaffirmed its medium-term guidance rather than raised it. This is the tension that defines the quarter.
What the numbers say about management's claims
Best-ever quarterly performance, surpassing Q1
Q2 revenue ₹361.01 Cr (vs ₹316 Cr Q1); PAT ₹27.95 Cr (vs ₹26.1 Cr Q1)
Supported
Dahej Phase 1 commissioning next month with trial runs
Trial runs confirmed for December; consistent with facility nearing completion on track
Supported (slipped from November, minor)
Confident in 14-15% EBITDA margins within 3 years
H1 FY27 EBITDA margin 11.07%; Q2 10.71%. Trajectory aligns with phased capacity and product mix shift to non-rubber (18% → 30%)
Supported (credible path)
Strong demand across OEM/tire/automotive sector
64% YoY revenue growth; October highest production ever; volume growth mid-teens confirmed in Q&A
Supported (exceeds mid-teen guidance)
Naidupeta 5K MTPA brownfield Q3 target, mid-January spillover acceptable
Management clarified Q3 target for ramp-up with mid-January full commissioning; timeline reasonable for brownfield
Supported (reasonable timeline)
What changed on this call
Dahej Phase 1 commissioning confirmed for December (vs. November prior guidance) — trial runs next month on track. FY27 revenue guidance now explicit: >₹1,200 Cr (vs. ₹361 Cr Q2, ₹677 Cr H1) — reaffirmed, not raised. This is significant: the company is doubling revenue every three years (₹600 Cr FY24 → ₹1,200+ Cr FY27), and this quarter's 64% growth is the deliverable of that plan, not a surprise. Non-rubber applications ramp clarified: 18% today → 30% target by FY29 — a new milestone for tracking margin expansion via product mix. EBITDA margin target 14-15% by FY29 reaffirmed on consolidated basis. All guidance held, none raised.
Why management isn't raising sights despite record execution
This is the conversation beneath the conversation. Management is laser-focused on two sequential events: (1) Dahej Phase 1 achieving customer qualifications and ramp-up (FY28 target 60-70% utilization), and (2) specialty product mix hitting 30% of revenue to unlock the 14-15% EBITDA margin. Until both are proven, guidance stays locked. The company is also carrying elevated working capital — inventory expanded ₹92→154 Cr in H1, receivables ₹177→207 Cr — and management acknowledged 90-100 day cycles are inherent to this growth phase. Translation: cash flow is good but capital-intensive; no room for surprises yet.
Our working capital intensity is about 90 to 100 days of working capital days. And even if we expect the run rate to continue where we are today for the next 2 quarters, our cash position would definitely improve. And as a company, we feel that any company which is in a high-growth phase, the cash flow from operations after working capital changes could be negative.
The bull-bear ledger
India's largest zinc oxide recycler (77K MTPA capacity) well-positioned to capture market share from fragmented competitors in consolidation wave
Volume growth corroborated: 64% YoY beats mid-teen guidance; October highest-ever production
Margin trajectory on track: H1 11.07% EBITDA margin tracking toward 11-12% Phase 1 guidance
Strong balance sheet: ₹63 Cr net cash, no external funding needed for Phase 2 capex even if growth maintained
Working capital build evident: Inventory ₹92→154 Cr, receivables ₹177→207 Cr in H1; 90-100 day cycle material if growth accelerates
Dahej Phase 1 ramp-up is sequential: customer qualifications → production ramp → utilization targets; delays could push FY29 targets to FY30+
Margin compression Q1→Q2: EBITDA margin 11.07%→10.71% (LME zinc lag explained; creates quarterly volatility)
New ventures still nascent: Recycled rubber (JG TUR), battery zinc oxide in pilot trials; 2-3 year commercialization timelines vague on quantified milestones
Risks, ranked by how much they should concern a holder
Dahej Phase 1 customer qualification and ramp-up execution
15K MTPA capacity must achieve customer qualifications and production ramp over 2-3 quarters to hit FY28 60-70% utilization target. Delays could push 14-15% EBITDA realization to FY30; would pressure FY28-29 guidance.
Medium
Zinc commodity price swings and LME lag volatility
Zinc oxide sold at LME-linked pricing; Q2 margin compression (11.07%→10.71%) driven by procurement lag. Sustained deflation or lag spikes could compress per-ton margins and create quarterly volatility.
Medium
Working capital intensity and cash flow timing
90-100 day cycle at ₹1,200+ Cr FY27 revenue run rate means ~₹300+ Cr tied up in inventory/receivables. If growth accelerates beyond plan or collections slip, could strain cash despite ₹63 Cr net cash buffer.
Medium
New product commercialization delays (recycled rubber, battery zinc oxide)
Non-rubber apps target 18%→30% by FY29 depends on JG TUR scaling and battery zinc oxide customer adoption. If adoption slower than 2-3 year timelines, specialty mix shift and margin lift could slip 1-2 years.
Medium
FII/institutional ownership decline and market skepticism
FII ownership down from 6.05% (FY25 Q4) to 3.21% (FY27 Q1); DII also trimmed. Stock down 17% from ATH despite record results. Suggests institutions pricing in execution risk, valuation reset, or rotation away from growth plays.
Medium-to-Low (market signal, not fundamental)
How the street is positioned
J.G. Chemicals trades at ₹575.75 as of 2026-11-05, down 17.15% from its all-time high of ₹694.9 but up 92.95% from its 52-week low of ₹298.4. The stock sits below its 20-day SMA (₹599.04) and 50-day SMA (₹607.12), above its 200-day SMA (₹461.45). RSI is 45.4 — neutral.
Post-result price action: The 17% drawdown from ATH despite delivering record results and beating volume guidance is the market's own verdict. This is not a selloff driven by misses; it's skepticism baked into a re-rating. The market is pricing in either: (1) execution risk on Dahej Phase 1 customer ramp, (2) doubt about specialty product mix and new ventures delivering on timeline, (3) working capital/cash flow concerns, or (4) valuation reset at prior ATH levels. None of these are fundamental surprises — they're all discussed on the call — but institutions are hedging them.
Institutional flows: FII ownership declined from 6.05% (FY25 Q4) to 3.21% (FY27 Q1) — a 284bp drop. DII also trimmed from 3.49% to 3.00%. Promoter ownership stable at 70.99%. This ownership shift is significant: large institutions are exiting or reducing exposure despite strong execution, reinforcing the view that the market is pricing in execution or valuation risk, not fundamentals.
Bulk/block deals (August 2026): Junomoneta Finsol Private Limited, HRTI Private Limited, and other financial entities rotated ₹620–₹656 range. No clear promoter insider selling. The bulk deal activity suggests some players see value at current levels, but the lack of sustained accumulation and the FII exit pattern suggests consensus skepticism.
1 · Dahej Phase 1 trial runs and customer qualifications (December 2026 onwards)
Q3 FY27 updates on production run-rate achieved, customer order visibility, and ramp trajectory for FY28. This is the de-risker for the long-term margin target. Key metric: are qualifications tracking on schedule, or are spillovers into Q4 FY27 appearing?
2 · Naidupeta 5K MTPA brownfield commissioning (Q3 FY27 / January 2027 ramp-up)
Confirm timeline slip from Q3 to mid-January is immaterial. Monitor whether new capacity is adding to revenue and utilization by Q4 FY27 / Q1 FY28.
3 · Non-rubber applications revenue contribution trajectory (Q3 / Q4 tracking)
Confirm 18%→30% shift is credible. If specialty product mix is stalling, margin expansion thesis to 14-15% FY29 gets pushed out. This is the linchpin of the guidance.
J.G. Chemicals is delivering on what it promised — record growth, capacity on schedule, margins on track. But the stock's 17% drawdown from ATH despite record results is not a market accident; it's the repricing of a steady-state expansion plan against expectations of a surprise inflection. The company's decision to reaffirm, rather than raise, medium-term guidance signals confidence in the long-term thesis but realism about execution risk and commodity swings.
The honest read is neither bull nor bear; it's pragmatic. The Dahej Phase 1 de-risker comes in Q3-Q4 FY27. If utilization ramps to 60-70% on schedule and specialty product mix flows toward 30%, the 14-15% FY29 EBITDA target is credible, and the ₹575 price will look cheap. If delays emerge or mix shifts slow, the drawdown could extend. The number to track from here is Dahej Phase 1 utilization and the trajectory to FY28 guidance — everything else flows from that execution.
JG Chemicals' consolidated PAT jumps 86% YoY to ₹28 Cr, margins expand
PAT +85.9% YoY · revenue +63.9% · margins expanding
₹361.01 Cr
+63.9% YoY
₹27.95 Cr
+85.9% YoY
7.73%
+1pp YoY
₹6.81
Consolidated revenue rose 63.9% YoY to ₹361.0 Cr (from ₹220.3 Cr) and 14.4% QoQ (from ₹315.7 Cr); consolidated PAT climbed 85.9% YoY to ₹27.95 Cr (from ₹15.03 Cr) and 7.0% QoQ (from ₹26.12 Cr), with PAT attributable to owners at ₹26.70 Cr and basic EPS of ₹6.81 versus ₹3.67 a year ago. Neither period carries exceptional items, so the comparison is clean, and profit growth outpacing revenue growth YoY makes this a strong print on both counts.
Q2 FY-2027 vs prior quarters
Operating margin (PBT adjusted for other income, finance cost and depreciation, over revenue) expanded to ~10.55% from 8.15% a year ago, driven mainly by cost of materials consumed falling to 84.6% of revenue from 86.0% YoY. Sequentially, operating margin was roughly flat versus Q1 FY27's 10.62%, but net margin slipped to 7.73% from 8.20% QoQ purely because other income fell to ₹0.58 Cr from ₹2.73 Cr — core operating profitability held up even as the headline net-margin ratio dipped. On a standalone (parent-only) basis, PAT grew a slower 59.0% YoY to ₹6.59 Cr versus the consolidated 85.9%, a meaningful divergence reflecting faster profit growth at subsidiary BDJ Oxides within the consolidated group.
The stock went into the print at ₹580.05, down 5% over the past month of trading.
For context: this is the second-highest quarterly PAT of the last 6 quarters; PAT has now risen for 4 consecutive quarters; revenue is at a 6-quarter high.
Dahej Phase 1 (15K–17K MTPA) commissioning Nov 2026, targeting 50–60% FY28 utilization and 11–12% EBITDA. Long-term target 14–15% EBITDA margin by FY29 via higher-value product mix and 40K+ capex additions. Expects consistent demand momentum through FY27; volume growth in mid-teens.
— This quarter: beat
Management's prior concall guided mid-teens volume growth and "consistent demand momentum" through FY27, alongside 50-60% FY28 utilization and 11-12% EBITDA margin at the under-construction Dahej Phase 1 line (15-17K MTPA); this quarter's 64% revenue growth and YoY margin expansion run well ahead of that trajectory — a beat. Dahej Phase 1 was guided to commission this very month (November 2026), so none of its capacity shows up in this print, making it the key swing factor for H2 FY27. No specific Street consensus estimate for this quarter could be found (vsStreet unknown); broader analyst commentary points to 15-20% FY27 PAT growth, a bar this quarter's YoY print comfortably outpaces on a run-rate basis. No company press release commentary was available for this filing. Alongside the results, the board appointed two independent directors (Kaushik Roy, ex-PCBL Chemical MD; Sunil Duggal, ex-Hindustan Zinc CEO) and filed an IPO-proceeds utilization report — both housekeeping items, not drivers of the print.
W1
Dahej Phase 1 (15-17K MTPA) commissioning guided for Nov 2026 — track progress toward management's 50-60% FY28 utilization and 11-12% EBITDA margin target for that unit
W2
Whether operating margin (10.55% this quarter) resumes sequential expansion toward management's 14-15% FY29 margin target as new capacity ramps
W3
Other income normalizing — fell to ₹0.58 Cr this quarter from ₹2.73 Cr last quarter; watch whether net margin reverts toward Q1's 8.2%
Source filed in ₹ Million, converted to ₹ Crore (÷10). No exceptional items in either period. Consolidated = parent + subsidiary BDJ Oxides Pvt Ltd; standalone PAT growth (+59% YoY) diverges materially from consolidated (+86% YoY) — consolidated used as primary.
Record quarter on strong momentum; Dahej Phase 1 imminent
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Buy
confidence 8/10
Grade A
Hit Dahej timeline (Dec vs Nov), Q2 EBITDA margin 10.7% tracking toward 11-12% Phase 1 guidance; volume growth 64% YoY beats mid-teen expectation.
Very Optimistic
next 1–2 quarters
Optimistic
multi-year
Delivered 64% YoY revenue growth and 86% PAT growth on strong zinc oxide demand and improving product mix. Dahej Phase 1 commissioning December will unlock 15K MTPA capacity, de-risking long-term 14-15% EBITDA target. Key risk: new capacity ramp-up execution and zinc commodity price swings.
₹361 Cr
Revenue · +63.9% YoY₹28 Cr
Reported PAT · +85.9% YoYExpanding
Margins · vs guidance: CorroboratedDid the claims hold up?
Best ever quarterly performance, surpassing Q1
METQ2 revenue ₹361.01 Cr (vs ₹316 Cr Q1), PAT ₹27.95 Cr (vs ₹26.1 Cr Q1), verified.
Dahej Phase 1 commissioning next month with trial runs
METTrial runs scheduled next month (December), consistent with prior Nov 2026 guidance. Facility nearing completion on track.
Confident in 14-15% EBITDA margins within 3 years
METH1 FY27 EBITDA margin 11.07%; Q2 10.71%. Trajectory aligns with phased capacity and product mix shift; credible path.
Strong demand across OEM/tire/automotive sector
METQ2 volume growth mid-teens (confirmed in Q&A); October highest production ever. 64% YoY revenue growth corroborates.
Naidupeta brownfield Q3 target, spillover to mid-January
MET5K MTPA addition planned. Management clarified Q3 target for ramp-up with mid-Jan full commissioning; reasonable timeline.
Earnings quality
What changed since the last call
Dahej Phase 1 commissioning confirmed
NeutralReaffirmed November → December timeline; trial runs next month. Stays on track. Prior guidance November, now December '26.
Long-term EBITDA target affirmed
Neutral14-15% by FY29 reconfirmed. Phase 1 was 11-12% spec; portfolio target reflects mix/Dahej contribution. Maintained, not raised.
FY27 revenue guidance explicit
NewManagement confirmed >₹1,200 Cr FY27 (vs Q1 ₹316 Cr). Doubling every 3 years strategy restated; new explicit floor for FY27.
Non-rubber apps growth trajectory
New18% → 30% target over 2-3 years stated explicitly. New near-term milestone; supports margin expansion narrative.
The Q&A
Analysts pressed on margin compression (Akshit), cash flow dynamics (Shreyans), and Dahej ramp timeline (Dhruvin). Management held firm on margin outlook and capacity delivery but acknowledged working capital intensity; tone reassuring, not defensive.
Volume growth trajectory — Shreyans Jain, 3A Capital
AnsweredMid-teen volume growth Q2; gross margins fluctuate quarter-to-quarter on zinc cost timing. Confident 14-15% EBITDA margin within 3 years with value-added product share increasing.
Capacity utilization and timeline — Dhruvin Kadakia, Monarch Networth Capital
AnsweredDahej next month; Naidupeta planned Q3 but spillover mid-Jan '27. 80% achievable utilization correct; Phase 2 mid-2028. Ample capacity to meet 6-9 month demand visibility.
Operating leverage and cost discipline — Dhruvin Kadakia, Monarch Networth Capital
AnsweredBuilt team before results arrived; growth won't scale 1:1 with headcount. Leverages should compound in quarters ahead as volume increases.
Gross margin drivers and raw material hedging — Akshit Shetty, Family Office
PartialLME pricing lag: lower cost material on order, arrived late or not yet. Higher cost domestic sourcing hitting before goods received. Averages out year-end. Per-ton focus, not only % margin; Q-on-Q volatility normal in zinc oxide business.
Zinc price sensitivity and volume — Virag Shah, Elios Financial Services
AnsweredAgnostic to zinc prices; volume is cornerstone of growth. FY28 Dahej utilization ~65-70%. Tire ~60-65%, non-tire ~35-40% (ceramics, specialty chemicals, pharma). Ceramic market large, base currently very low.
Dahej Phase 1 revenue potential — Param Shah, Carnelian Capital
AnsweredINR900 Cr should be closer to FY29-FY30, period in which Dahej and Naidupeta capacities fully commissioned. Peak potential higher than INR900 Cr based on valuations. Phase 2 mid-2028 start.
Recycled rubber business prospects — Virag Shah, Elios Financial Services
AnsweredPilot trials with key customers successful. Engaging in deeper trials; full-scale industrial venture on drawing board; infrastructure planned. Very buoyant on ESG tailwinds and customer demand.
Specialty zinc sulphate and battery zinc oxide — Manish Reddy, Investor
AnsweredSulphate utilization ~50% Naidupeta; ramp up next 2-3 months via R&D and new customer qualifications. Revenue share 5-7% expected. Battery zinc: international initiative, only Indian benchmarked producer. Customers scaling; next 2-3 years volumes will grow as scale-up happens.
Solar power and debt trajectory — Vinit Thakur, Plus 91 AMC
AnsweredSolar Phase 1 operational, 25-30% energy met. Regulations under review for capacity increase. ~4-year payback. Net cash ₹63 Cr end Sept '26; doubling revenue won't require external borrowing.
Non-rubber applications diversification — Vinit Thakur, Plus 91 AMC
AnsweredFY24 10%, FY26 18% now. Ceramics, pharmacy, specialty chemicals, coatings growing at 8% Indian economy rate. Recycled product advantage; competitors can't meet blend specs. Next 2-3 years gradual shift; close to 30% margin, contributes to 14-15% EBITDA.
Guidance
FY27 revenue >₹1,200 Cr (vs ₹361 Cr Q2; ₹676.66 Cr H1)
HighExplicit in Q&A; consistent with doubling every 3 years strategy (₹600 Cr FY24 → ₹1,200+ Cr FY27). Dahej ramp-up supports.
Dahej Phase 1 revenue potential ~₹900 Cr by FY29-FY30
Medium15K MTPA at full utilization; FY28 targeting 60-70% utilization. Peak potential stated as higher; timing FY29-30 based on ramp curve.
14-15% EBITDA margin by FY29 on consolidated basis
HighReaffirmed from prior guidance. Backed by Dahej Phase 1/2, product mix shift to specialty grades (+18% → 30% non-rubber apps), and operating leverage.
Current EBITDA margin sustainable and expanding
MediumQ2 10.71%, H1 11.07%. Management confident current level sustainable; sees expansion path via new capacity, specialization, and less commodity exposure.
Dahej Phase 1 capex completion next month (December 2026)
HighTrial runs scheduled; on track vs November guidance. Phase 2 capex to start mid-2028.
Naidupeta 5K MTPA brownfield addition Q3/Q4 FY27 (mid-Jan commissioning)
HighBrownfield ramp-up; R&D center recently inaugurated. Management confident in timeline; minor spillover to Jan acceptable.
Risks the call surfaced
Capacity ramp-up execution
MediumDahej Phase 1 (15K MTPA) and Naidupeta (5K MTPA) commissioning next 2 months. Trial runs, customer quals, production ramp-up are sequential. Delays could impact FY28 utilization/revenue.
Zinc commodity price exposure
MediumZinc oxide sold at LME-linked pricing; input costs similarly indexed. Price swings create gross margin volatility (Q2 vs Q1 margin compression evident). Per-ton model hedges some, but sustained deflation could pressure.
Working capital intensity
MediumInventory expanded INR92→154 Cr, receivables INR177→207 Cr in H1 FY27. At 90-100 days, cyclical build is expected in growth phase, but accelerating sales growth could strain cash.
New product/venture execution risk
MediumRecycled rubber (JG TUR), battery-grade zinc oxide, and specialty chemical grades are nascent. Pilot trials underway but full commercialization and scale remain uncertain. Revenue contribution assumptions may slip.
Tier-1 tire OEM concentration
MediumWhile not explicitly stated, tire/rubber remains core segment (60-65% of sales). Tier-1 OEM concentration likely; customer defection or order loss could impact volume.
Management
Score 8/10. Clear, candid on constraints (margin volatility, working capital, zinc price exposure). Provides specific numbers and timelines. Acknowledges limitations (e.g., ceramic adoption slower than hoped) without over-promising. Track record strong: Dahej Phase 1 on timeline (Dec vs Nov), Q2 volume growth 64% vs mid-teen guidance, margin progression H1 tracking toward targets. No material misses disclosed.
1 · December 2026
Dahej Phase 1 trial runs, initial customer qualifications
2 · Q3 FY27 / Jan 2027
Naidupeta 5K MTPA brownfield commissioned, +5% capacity
3 · Mid-2028
Dahej Phase 2 (25K MTPA additional) capex start
Key risk: new capacity ramp-up execution and zinc commodity price swings.